Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia

Blood Adv. 2020 Jan 28;4(2):296-300. doi: 10.1182/bloodadvances.2019000586.

¹ Children's Cancer Institute, School of Women's and Children's Health, University of New South Wales Sydney, Sydney, NSW, Australia.
² Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.
³ Registry of Older South Australians, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
⁴ Adelaide Oncology and Haematology, Adelaide, SA, Australia.
⁵ Medicines Research Centre, GlaxoSmithKline, Stevenage, United Kingdom; and.
⁶ Drug Discovery and Development, Cancer Research Institute, University of South Australia, Adelaide, SA, Australia.

Abstract

Cyclin-dependent kinase 9 and bromodomain and extraterminal inhibitors are synergistic in MLL-rearranged leukemia.
Multiple AML driver genes are downregulated by the combined therapy suggesting broad applicability for this subtype.